All In Biotech

Drug Trial Radar · NCT00251719

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once-daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis

Last checked: Nov 20, 2026Latest source record: Feb 3, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,054 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,054

Actual

Start

Dec 2005

Primary completion

Jan 2007

Study completion Jan 2007

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Nov 10, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to assess the efficacy and safety of 8 weeks of treatment with Dexlansoprazole modified release (MR)(60 mg daily and 90 mg daily) compared to Lansoprazole (30 mg daily) in healing subjects with endoscopically proven erosive esophagitis.

Conditions

  • Esophagitis, Reflux
  • Esophagitis, Peptic

Interventions

  • Dexlansoprazole MRDrug

    Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.

  • Dexlansoprazole MRDrug

    Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.

  • LansoprazoleDrug

    Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Crude Rate Analysis.Time frame: 8 Weeks
  2. Percentage of Subjects With Complete Healing of Erosive Esophagitis by Week 8 as Assessed by Endoscopy - Life Table MethodTime frame: 8 Weeks

Locations

144 sites in 16 countries. Site status is shown where the registry gives one.

  • Site not named

    Anniston, Alabama

  • Site not named

    Hueytown, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Tallassee, Alabama

  • Site not named

    Tuscaloosa, Alabama

  • Site not named

    Tucson, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    North Little Rock, Arkansas

  • Site not named

    Azusa, California

  • Site not named

    Carmichael, California

  • Site not named

    Cypress, California

  • Site not named

    Fresno, California

  • Site not named

    Los Angeles, California

  • Site not named

    Modesto, California

  • Site not named

    Newport Beach, California

  • Site not named

    Oakland, California

  • Site not named

    Orange, California

  • Site not named

    San Diego, California

  • Site not named

    Santa Maria, California

  • Site not named

    Littleton, Colorado

  • Site not named

    Longmont, Colorado

  • Site not named

    Wheat Ridge, Colorado

  • Site not named

    Bristol, Connecticut

  • Site not named

    Newark, Delaware

  • Site not named

    Fort Myers, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Naples, Florida

  • Site not named

    New Smyrna Beach, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    Port Orange, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Zephyrhills, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Moline, Illinois

  • Site not named

    North Chicago, Illinois

  • Site not named

    Oak Forest, Illinois

  • Site not named

    Evansville, Indiana

Showing 40 of 144 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.